Peregrine Pharmaceuticals Company Profile (NASDAQ:PPHM)

About Peregrine Pharmaceuticals (NASDAQ:PPHM)

Peregrine Pharmaceuticals logoPeregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. Bavituximab is its lead immunotherapy candidate. Bavituximab is a monoclonal antibody that targets and binds to phosphatidylserine (PS), a immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then flips and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. The Company's subsidiary is Avid Bioservices, Inc. (Avid). Avid provides integrated current good manufacturing practices (cGMP) services from cell line development to commercial biomanufacturing.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PPHM
  • CUSIP: N/A
  • Web: www.peregrineinc.com
Capitalization:
  • Market Cap: $168.5 million
  • Outstanding Shares: 297,709,000
Average Prices:
  • 50 Day Moving Avg: $0.59
  • 200 Day Moving Avg: $0.47
  • 52 Week Range: $0.28 - $0.77
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.32
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $58.51 million
  • Price / Sales: 2.88
  • Book Value: $0.15 per share
  • Price / Book: 3.82
Profitability:
  • EBIDTA: ($32,410,000.00)
  • Net Margins: -80.49%
  • Return on Equity: -90.82%
  • Return on Assets: -39.53%
Debt:
  • Current Ratio: 1.25%
  • Quick Ratio: 0.86%
Misc:
  • Average Volume: 2.46 million shs.
  • Beta: 1.26
  • Short Ratio: 0.63
 

Frequently Asked Questions for Peregrine Pharmaceuticals (NASDAQ:PPHM)

What is Peregrine Pharmaceuticals' stock symbol?

Peregrine Pharmaceuticals trades on the NASDAQ under the ticker symbol "PPHM."

How were Peregrine Pharmaceuticals' earnings last quarter?

Peregrine Pharmaceuticals (NASDAQ:PPHM) announced its earnings results on Monday, March, 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.01. The business had revenue of $10.75 million for the quarter, compared to analyst estimates of $14.02 million. Peregrine Pharmaceuticals had a negative return on equity of 90.82% and a negative net margin of 80.49%. The business's revenue for the quarter was up 60.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.08) EPS. View Peregrine Pharmaceuticals' Earnings History.

When will Peregrine Pharmaceuticals make its next earnings announcement?

Peregrine Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, July, 12th 2017. View Earnings Estimates for Peregrine Pharmaceuticals.

Where is Peregrine Pharmaceuticals' stock going? Where will Peregrine Pharmaceuticals' stock price be in 2017?

3 brokerages have issued 12-month price objectives for Peregrine Pharmaceuticals' stock. Their predictions range from $0.50 to $1.50. On average, they anticipate Peregrine Pharmaceuticals' share price to reach $1.00 in the next twelve months. View Analyst Ratings for Peregrine Pharmaceuticals.

Are investors shorting Peregrine Pharmaceuticals?

Peregrine Pharmaceuticals saw a increase in short interest in May. As of May 15th, there was short interest totalling 1,346,214 shares, an increase of 21.9% from the April 28th total of 1,104,400 shares. Based on an average trading volume of 968,467 shares, the short-interest ratio is presently 1.4 days.

Who are some of Peregrine Pharmaceuticals' key competitors?

Who are Peregrine Pharmaceuticals' key executives?

Peregrine Pharmaceuticals' management team includes the folowing people:

  • Carlton M. Johnson Jr., Independent Chairman of the Board
  • Steven W. King, President, Chief Executive Officer, Director
  • Paul J. Lytle, Chief Financial Officer
  • Mark R. Ziebell, Vice President, General Counsel, Corporate Secretary
  • Shelley P.M. Fussey Ph.D., Vice President - Intellectual Property
  • Joseph S. Shan, Vice President - Clinical & Regulatory Affairs
  • David H. Pohl, Independent Director
  • Eric S. Swartz, Independent Director

Who owns Peregrine Pharmaceuticals stock?

Peregrine Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include RONIN CAPITAL, LLC (6.80%), Kennedy Capital Management Inc. (2.93%), Vanguard Group Inc. (2.08%), Renaissance Technologies LLC (1.03%), Geode Capital Management LLC (0.48%) and Eqis Capital Management Inc. (0.35%). View Institutional Ownership Trends for Peregrine Pharmaceuticals.

Who sold Peregrine Pharmaceuticals stock? Who is selling Peregrine Pharmaceuticals stock?

Peregrine Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. View Insider Buying and Selling for Peregrine Pharmaceuticals.

Who bought Peregrine Pharmaceuticals stock? Who is buying Peregrine Pharmaceuticals stock?

Peregrine Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Kennedy Capital Management Inc., Acadian Asset Management LLC, Renaissance Technologies LLC, Brown Advisory Securities LLC, Geode Capital Management LLC, Morgan Stanley and Russell Investments Group Ltd.. View Insider Buying and Selling for Peregrine Pharmaceuticals.

How do I buy Peregrine Pharmaceuticals stock?

Shares of Peregrine Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Peregrine Pharmaceuticals' stock price today?

One share of Peregrine Pharmaceuticals stock can currently be purchased for approximately $0.57.


MarketBeat Community Rating for Peregrine Pharmaceuticals (NASDAQ PPHM)
Community Ranking:  3.6 out of 5 (  )
Outperform Votes:  108 (Vote Outperform)
Underperform Votes:  42 (Vote Underperform)
Total Votes:  150
MarketBeat's community ratings are surveys of what our community members think about Peregrine Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Peregrine Pharmaceuticals (NASDAQ:PPHM) (?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $1.00 (76.68% upside)

Analysts' Ratings History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/6/2017Noble FinancialReiterated RatingBuyMediumView Rating Details
9/13/2016Roth CapitalReiterated RatingNeutral$0.50N/AView Rating Details
9/12/2016FBR & CoReiterated RatingOutperform$1.00N/AView Rating Details
6/1/2015MLV & Co.Reiterated RatingBuy$3.50N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Earnings by Quarter for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Earnings History by Quarter for Peregrine Pharmaceuticals (NASDAQ:PPHM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/12/2017        
3/13/2017Q3 2017($0.03)($0.04)$14.02 million$10.75 millionViewN/AView Earnings Details
12/12/2016Q217($0.03)($0.02)$587.49 million$23.40 millionViewN/AView Earnings Details
9/8/2016Q1($0.04)($0.05)$13.08 million$5.61 millionViewN/AView Earnings Details
7/14/2016Q416($0.03)($0.05)$15.80 million$18.78 millionViewListenView Earnings Details
3/9/2016Q316($0.07)($0.08)$7.96 million$6.71 millionViewListenView Earnings Details
12/10/2015Q216($0.09)($0.07)$7.35 million$9.52 millionViewListenView Earnings Details
9/9/2015Q116($0.08)($0.08)$7.96 million$9.67 millionViewN/AView Earnings Details
7/14/2015Q315($0.08)($0.07)$6.42 million$9.31 millionViewListenView Earnings Details
3/12/2015Q215($0.08)($0.08)$4.20 million$5.68 millionViewN/AView Earnings Details
12/10/2014Q115($0.07)($0.07)$5.82 million$6.30 millionViewN/AView Earnings Details
9/9/2014Q1($0.06)($0.08)$5.76 million$5.50 millionViewListenView Earnings Details
7/14/2014Q414($0.07)($0.06)$4.75 million$6.47 millionViewN/AView Earnings Details
3/7/2014Q314($0.06)($0.06)$5.09 million$3.90 millionViewN/AView Earnings Details
12/10/2013Q2($0.05)($0.05)$5.74 million$7.35 millionViewListenView Earnings Details
9/9/2013Q1 2014($0.05)($0.05)$4.75 million$4.69 millionViewN/AView Earnings Details
7/11/2013Q4 2013($0.06)($0.06)$3.57 million$4.25 millionViewN/AView Earnings Details
3/12/2013Q3 2013($0.07)($0.04)$3.90 million$7.04 millionViewN/AView Earnings Details
12/10/2012-0.08($0.09)($0.08)$4.03 million$4.03 millionViewN/AView Earnings Details
9/10/2012Q113($0.11)($0.07)$3.97 million$4.25 millionViewN/AView Earnings Details
7/16/2012($0.13)($0.10)ViewN/AView Earnings Details
3/9/2012($0.13)($0.13)ViewN/AView Earnings Details
12/12/2011($0.13)($0.16)ViewN/AView Earnings Details
9/9/2011($0.14)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Peregrine Pharmaceuticals (NASDAQ:PPHM)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.05)($0.03)($0.04)
Q2 20171($0.04)($0.04)($0.04)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Latest Headlines for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Source:
DateHeadline
americanbankingnews.com logoPeregrine Pharmaceuticals (PPHM) Short Interest Up 21.9% in May
www.americanbankingnews.com - May 28 at 9:06 AM
nasdaq.com logoImplied Volatility Surging for Peregrine Pharmaceuticals (PPHM) Stock Options - Nasdaq
www.nasdaq.com - May 5 at 12:29 AM
americanbankingnews.com logoSomewhat Favorable Media Coverage Somewhat Likely to Affect Peregrine Pharmaceuticals (PPHM) Stock Price
www.americanbankingnews.com - May 4 at 9:24 PM
zacks.com logoImplied Volatility Surging for Peregrine Pharmaceuticals (PPHM) Stock Options
www.zacks.com - May 4 at 8:20 AM
finance.yahoo.com logoETFs with exposure to Peregrine Pharmaceuticals, Inc. : May 2, 2017
finance.yahoo.com - May 2 at 5:07 PM
finance.yahoo.com logoMilliporeSigma's Mobius(R) 2,000-liter Single-use Bioreactors to Expand Avid Bioservices' Manufacturing Capabilities
finance.yahoo.com - May 1 at 11:20 AM
americanbankingnews.com logoPeregrine Pharmaceuticals (PPHM) Short Interest Update
www.americanbankingnews.com - April 28 at 7:09 AM
americanbankingnews.com logoPeregrine Pharmaceuticals (PPHM) Earns Daily News Sentiment Rating of 0.36
www.americanbankingnews.com - April 27 at 5:26 PM
americanbankingnews.com logoPositive Media Coverage Likely to Impact Peregrine Pharmaceuticals (PPHM) Stock Price
www.americanbankingnews.com - April 24 at 5:46 PM
investorplace.com logoPeregrine Pharmaceuticals (PPHMP) Leads 14 Activist Investor Reports
investorplace.com - April 20 at 10:45 AM
americanbankingnews.com logoSomewhat Favorable News Coverage Likely to Affect Peregrine Pharmaceuticals (PPHM) Share Price
www.americanbankingnews.com - April 18 at 9:15 PM
finance.yahoo.com logoETFs with exposure to Peregrine Pharmaceuticals, Inc. : April 11, 2017
finance.yahoo.com - April 11 at 7:08 PM
americanbankingnews.com logoPeregrine Pharmaceuticals' (PPHM) "Buy" Rating Reiterated at Noble Financial
www.americanbankingnews.com - April 7 at 10:07 PM
finance.yahoo.com logoPeregrine Pharmaceuticals Highlights Clinical Data Presentation at AACR 2017 Annual Meeting Supporting Potential of Bavituximab to Enhance Anti-tumor Activity of Immunotherapy
finance.yahoo.com - April 7 at 12:00 PM
streetinsider.com logoPeregrine Pharma (PPHM) Announces Presentation of Preclinical ... - StreetInsider.com
www.streetinsider.com - April 4 at 4:47 AM
finance.yahoo.com logoPeregrine Pharmaceuticals Announces Presentation of Preclinical Study Results Highlighting Potential of PS-Targeting Antibodies to Enhance Anti-Tumor Activity of Adoptive T Cell Transfer Therapy with No Added Off-Target Toxicities
finance.yahoo.com - April 3 at 9:08 AM
finance.yahoo.com logoBiotech Industry Continues to Provide Investors with Gains in 2017: Today's Reports on Peregrine Pharmaceuticals and Novavax
finance.yahoo.com - March 27 at 9:39 AM
streetinsider.com logoPeregrine Pharma (PPHM) Says Five Abstracts Accepted for ... - StreetInsider.com
www.streetinsider.com - March 23 at 7:46 PM
streetinsider.com logoPeregrine Pharma (PPHM) Says Five Abstracts Accepted for Presentation at AACR
www.streetinsider.com - March 23 at 8:37 AM
finance.yahoo.com logoPeregrine Pharmaceuticals Announces Five Abstracts Accepted for Presentation at AACR 2017 Annual Meeting
finance.yahoo.com - March 23 at 8:37 AM
finance.yahoo.com logoAvid Bioservices Receives Mutliple 2017 CMO Leadership Awards for Quality, Reliability, Capabilties, Expertise and Compatibility
finance.yahoo.com - March 23 at 8:37 AM
finance.yahoo.com logoPEREGRINE PHARMACEUTICALS INC Financials
finance.yahoo.com - March 17 at 7:28 PM
seekingalpha.com logoPeregrine Pharmaceuticals' (PPHM) CEO Steve King on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - March 14 at 10:10 AM
americanbankingnews.com logoPeregrine Pharmaceuticals (PPHM) Issues Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - March 14 at 2:14 AM
us.rd.yahoo.com logoPeregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2017 and Recent Developments
us.rd.yahoo.com - March 13 at 7:00 PM
us.rd.yahoo.com logo4:10 pm Peregrine Pharma misses by $0.01, misses on revs; guides FY17 revs above estimate
us.rd.yahoo.com - March 13 at 7:00 PM
biz.yahoo.com logoPEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclo
us.rd.yahoo.com - March 13 at 7:00 PM
biz.yahoo.com logoQ3 2017 Peregrine Pharmaceuticals Inc Earnings Release - After Market Close
biz.yahoo.com - March 13 at 9:43 AM
americanbankingnews.com logoShort Interest in Peregrine Pharmaceuticals (PPHM) Grows By 570.4%
www.americanbankingnews.com - March 10 at 11:04 AM
finance.yahoo.com logoPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
finance.yahoo.com - March 9 at 7:09 PM
biz.yahoo.com logoPEREGRINE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 9 at 7:09 PM
finance.yahoo.com logoPeregrine to Report Financial Results for Third Quarter of Fiscal Year 2017 After Market Close on March …
finance.yahoo.com - March 6 at 6:42 PM
feeds.benzinga.com logoPeregrine to Report Financial Results for Third Quarter of Fiscal Year 2017 After Market Close on March 13, 2017
feeds.benzinga.com - March 6 at 8:38 AM
prnewswire.com logoBiotech Stocks Under Scanner -- Immunomedics, Peregrine Pharma, Vericel, and Biogen - PR Newswire (press release)
www.prnewswire.com - March 1 at 8:22 AM
finance.yahoo.com logoAvid Bioservices to Participate at Upcoming Life Sciences Industry Conferences
finance.yahoo.com - February 22 at 9:23 AM
rttnews.com logoPeregrine Pharmaceuticals Inc. (PPHM) Has Surged To Over An 8-Month High
www.rttnews.com - February 17 at 8:10 PM
investopedia.com logoPeregrine Cancer Test Clears Proof of Concept (PPHM)
www.investopedia.com - February 11 at 7:22 PM
streetinsider.com logoPeregrine Pharma (PPHM) Says Recent Publication Highlights Proof-of-Concept Data for Exosome-Based Cancer Detection Platform
www.streetinsider.com - February 10 at 9:08 PM
finance.yahoo.com logoCan the Rally in Peregrine Pharmaceuticals (PPHM) Shares Continue?
finance.yahoo.com - February 10 at 9:08 PM
investopedia.com logoPeregrine Cancer Test Clears Proof of Concept
www.investopedia.com - February 10 at 9:08 PM
streetinsider.com logoPeregrine Pharma (PPHM) Says Recent Publication Highlights Proof-of-Concept Data for Exosome-Based Cancer ... - StreetInsider.com
www.streetinsider.com - February 10 at 2:50 AM
finance.yahoo.com logoRecent Publication Highlights Proof-of-Concept Data Supporting the Diagnostic Potential of Phosphatidylserine-Positive Exosomes in Ovarian Cancer
finance.yahoo.com - February 9 at 9:49 PM
finance.yahoo.com logo8:06 am Peregrine Pharma announces the publication of positive proof-of-concept data for a novel exosome-based cancer detection platform
finance.yahoo.com - February 9 at 9:49 PM

Social

Chart

Peregrine Pharmaceuticals (PPHM) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff